VSBC 10-K & 10-Q changes, risk factors and insider trading
Vitaspring Biomedical Co. Ltd. · OTC · Services-Commercial Physical & Biological Research · CIK 1697884 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
Largest changes
As of January 31,see in full comparison2025,2026, we owed $2,411,000 to a related-party vendor, which is owned by our former officer, and$810,105$1,037,983 in advances from related parties, including advances made by a former Chief Executive Officer and Chairman of the Board. These obligations are unsecured, and are not subject to formal long-term repayment schedules, and may be payable on demand. On May 18, 2026, the Company entered into a deferred payment agreement for its accounts payable with a relatedparty,party.bothBoth parties agreed to defer collection efforts for a period of twenty-four (24) months from May 18,2026, and the related party will not demand immediate repayment of the outstanding balance.2026. The continuation of related-party financial support is not assured.
Full comparison: every changed paragraph (1)
As of January 31, 2025,2026, we owed $2,411,000 to a related-party vendor, which is owned by our former officer, and $810,105$1,037,983 in advances from related parties, including advances made by a former Chief Executive Officer and Chairman of the Board. These obligations are unsecured, and are not subject to formal long-term repayment schedules, and may be payable on demand. On May 18, 2026, the Company entered into a deferred payment agreement for its accounts payable with a related party,party. bothBoth parties agreed to defer collection efforts for a period of twenty-four (24) months from May 18, 2026, and the related party will not demand immediate repayment of the outstanding balance.2026. The continuation of related-party financial support is not assured.
Management's Discussion & Analysis (MD&A)
Removed heading “Allowance for Credit Losses”
Removed heading “Lease Accounting”
Removed heading “Stock-Based Compensation”
Removed heading “Fair Value of Financial Instruments”
Largest changes
Operating expenses were $385,411 for the year ended January 31, 2026, compared with $679,914 for the year ended January 31,see in full comparison2025, compared with $1,118,562 for the prior fiscal year.2025. For the years ended January 31,2025,2026, and2024,2025, the operating expenses were primarily attributed to professional fees of$180,700$125,673 and$283,070,$180,700, stock-based compensation of$109,911$0 and$164,865,$109,911, lease expenses of$99,171$0 and$255,210,$99,171,payrollsalary and related expenses of$252,041$231,250 and$138,730,$252,041, depreciation of $9,957 and$15,062,$9,957,impairmentfranchise interest and penalty related to delay payment ofequipmentfranchise tax of$0$555 and$10,449$0, and general and administrative expenses of$28,134$17,976 and$251,176,$28,135, respectively.
“The Company follows ASU 2022-03, ASC Subtopic “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions” (“ASC 820”), which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. …”see in full comparison
Full comparison: every changed paragraph (33)
Operating expenses were $385,411 for the year ended January 31, 2026, compared with $679,914 for the year ended January 31, 2025, compared with $1,118,562 for the prior fiscal year.2025. For the years ended January 31, 2025,2026, and 2024,2025, the operating expenses were primarily attributed to professional fees of $180,700$125,673 and $283,070,$180,700, stock-based compensation of $109,911$0 and $164,865,$109,911, lease expenses of $99,171$0 and $255,210,$99,171, payrollsalary and related expenses of $252,041$231,250 and $138,730,$252,041, depreciation of $9,957 and $15,062,$9,957, impairmentfranchise interest and penalty related to delay payment of equipmentfranchise tax of $0$555 and $10,449$0, and general and administrative expenses of $28,134$17,976 and $251,176,$28,135, respectively.
We did not record a current income tax provision on our operating losses for the years ended January 31, 20252026, and 2024,2025, due to our net operating loss position and a full valuation allowance against deferred tax assets. However, during the yearyears ended January 31, 2026, and 2025, we recognized $95,008$29,957 and $95,008, respectively, in interest and penalties on historical income tax obligations relating to fiscal year 2022. In accordance with ASC 740-10-45,740-10-45-25, these amounts are classified as income tax expense in our statementstatements of operations.
We had a net loss of $415,368 for the year ended January 31, 2026, compared to $774,922 for the year ended January 31, 2025. The decrease in net loss of $359,554 was primarily due to lower operating expenses, including reductions in professional fees, lease expenses, stock-based compensation, salary and related expenses, and general and administrative costs and reduced in provision for income tax expenses.
We had a net loss of $774,922 for the year ended January 31, 2025, compared to $1,118,562 for the year ended January 31, 2024. The decrease in net loss of $343,640 was due to a reduction in operating expenses of $438,648 offset by provision for income taxes of $95,008.
As of January 31, 2025,2026, and 2024,2025, current assets were comprised of $272$2,084 and $13$272 in cashcash, $8,443 and $0 and $23,614 in deposits,prepaid expense respectively.
As of January 31, 2025,2026, and 2024,2025, current liabilities were comprised of $2,411,000 and $2,411,000 in accounts payable - related party, $494,751$652,027 and $339,001$494,751 in accounts payable and other payables, $313,722$344,234 and $218,714$313,722 in income tax payable,and $0franchise tax payable and $93,334 in operating lease liabilities$1,037,983 and $810,105 and $425,482 in advances from related parties, respectively.
Our working capital deficiency increased by $565,402,$405,411, or 16.32%,10.06%, to $4,029,306$4,434,717 as of January 31, 2025,2026, compared to working capital deficiency of $3,463,904$4,029,306 as of January 31, 2024.2025. The increase was primarily due to an increase in advances from related parties,party, accounts payable and other payable and increase in income tax payable, offset by a decrease in operating lease liabilities and current assets.payable. The advances paid directly by related parties on our behalf for operating expenses are reflected as operating activities, while cash proceeds received directly from related parties are classified as financing activities. A substantial portion of our liabilities consistconsists of obligations to related parties that are unsecured, non-interest-bearing, and payable on demand, with no formal repayment terms.terms, our related party accounts payable is subject to the May 18, 2026, deferral agreement. Given our current financial condition, there can be no assurance that we will be able to continue operations absent additional capital. We may be required to significantly curtail or cease operations if financing is not obtained in the near term.
We did not record a current income tax provision on our operating losses for the years ended January 31, 2026, and 2025, due to our net operating loss position and a full valuation allowance against deferred tax assets.
However, during the years ended January 31, 2026, and 2025, we recognized $29,957 and $95,008, respectively, in interest and penalties on historical income tax obligations relating to fiscal year 2022. In accordance with ASC 740-10-45-25, these amounts are classified as income tax expense in our statements of operations.
The income tax payable balance primarily relates to historical tax liabilities, and no current income tax expense was recognized due to our net operating loss position and full valuation allowance. During the year ended January 31, 2025, we recognized $95,008 interest and penalty payable related to fiscal year 2022.
We have not generated positive cash flows from operating activities. For the year ended January 31, 2025,2026, net cash flows used in operating activities was $14,675,$2,688, consisting of a net loss of $774,922,$415,368, reduced by depreciation expense of $9,957, non-cash lease expenses of $89,652, stock-based compensation of $109,911, advances from related party for operating expenses of $369,689,$223,378, income tax expenses payable of $95,008$29,957, franchise interest and penalty payable of $555 and reduced by a net change in working capital of $86,030.$148,833.
For the year ended January 31, 2024,2025, net cash flows used in operating activities was $34,920,$14,675, consisting of a net loss of $1,118,562,$774,922, reduced by depreciation expensesexpense of $15,062, impairment of equipment of $10,449,$9,957, non-cash lease expenses of $166,030,$89,652, stock-based compensation of $164,865,$109,911, advances from related party for operating expenses of $205,523,$369,689, accountsincome receivabletax expenses payable of $380,000$95,008 and reduced by a net change in working capital of $141,713.$86,030.
During the years ended January 31, 2025,2026, and 2024,2025, we had financing inflow of $14,934$4,500 and $5,277$14,934 from advances from related party,parties, respectively.
We evaluate our ability to continue as a going concern in accordance with ASC 205-40, Presentation of Financial Statements — Going Concern. This evaluation requires us to assess whether conditions or events raise substantial doubt about our ability to meet our obligations as they become due during the twelve months following the issuance of these financial statements. As discussed in Note 2 to the financial statements, thewe Company hashave limited liquidity and substantial obligations that may be payable on demand.
Our financial statements have been prepared assuming we will continue as a going concern. As of January 31, 2025,2026, we had a net loss of $774,922,$415,368, an accumulated deficit of $5,281,503,$5,696,871, a working capital deficiency of $4,029,306,$4,434,717, and negative operating cash flowsflow of $14,675,$2,688, which is due to our limited operations. These factors raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these financial statements.
Our ability to continue as a going concern depends upon our ability to obtain additional funding, restructuring advances from related parties, and implement a business plan that generates sustainable revenues. There can be no assurance that we will be successful in these efforts. No adjustments have been made to the carrying amounts of assets or liabilities should the Companywe be unable to continue as a going concern. Management’s plans include seeking additional equity financing, negotiating extensions of related-party obligations, and reducing discretionary operating expenditures.
Our financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of financial statements requires management to make estimates and assumptions, including, but not limited to,to stock-basedtax compensation,expense leasevaluation liabilities,allowances and the assessment of our ability to continue as a going concern assessment.concern. Our significant accounting policies are described in Note 3 to the financial statements. We consider the following policies and estimates to be critical because they involve significant judgments and assumptions and could materially affect our financial condition and results of operations. Critical estimates are those estimates that in accordance with U.S. GAAP, involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial statements. Management has determined that our most critical accounting estimates are those relating to stock-based compensation, lease accounting, and going concern assessment.
Allowance for Credit Losses
We evaluate financial assets measured at amortized cost, including accounts receivable, for expected credit losses under ASC 326. The estimate incorporates historical loss experience, current economic conditions, and reasonable and supportable forecasts. Changes in these factors could materially affect the allowance recorded.
Lease Accounting
Under ASC 842, we recognize right-of-use assets and lease liabilities for operating leases. When the implicit rate in a lease is not readily determinable, we estimate an incremental borrowing rate based on available market information and our credit profile. Changes in assumptions regarding discount rates could impact lease liabilities and related expenses.
Stock-Based Compensation
We account for equity-based awards under ASC 718. The fair value of equity awards is measured at the grant date and recognized over the requisite service period. The determination of fair value may require management to make assumptions regarding expected term, volatility, and other valuation inputs, as applicable.
In accordance with ASC 205-40, we evaluate whether conditions or events raise substantial doubt about our ability to continue as a going concern within one year from the issuance date of the financial statements. This assessment requires management to evaluate liquidity, forecasted cash flows, and the availability of financing or related-party support. As discussed in Note 2 of the financial statements, thewe Company hashave limited liquidity and substantial obligations that may be payable on demand.
Fair Value of Financial Instruments
The Company follows ASU 2022-03, ASC Subtopic “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions” (“ASC 820”), which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
Level 1
Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
Level 2
Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
Level 3
Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
The carrying amounts shown of the Company’s financial instruments including cash and cash equivalents and accounts payable approximate fair value due to the short-term maturity of these instruments.
What changed in the latest 10-Q
Risk Factors
New heading “The risk factors set forth below are restated in their entirety and supersede the risk factors disclosed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended January 31, 2026.”
New heading “We currently depend on a single supplier for all of our products, and we have no written supply agreement.”
New heading “Our supplier is a related party, which creates conflicts of interest.”
New heading “We have not entered into any sales agent or clinic supply agreements.”
New heading “We will need additional capital to purchase inventory before we can resume sales.”
New heading “Our target markets are outside the United States and are subject to evolving regulation and geopolitical risk.”
New heading “We depend on a small number of personnel whose compensation is accrued and unpaid.”
New heading “We depend on advances from a former officer and major shareholder who is under no obligation to continue funding us.”
New heading “Due to Related Party”
Removed heading “Because we currently have a stockholders’ deficit and lack independent directors, we may not satisfy the financial and governance requirements necessary to uplist to OTCQB or a national securities exchange.”
Largest changes
“Our initial target markets are Taiwan, Mainland China and Southeast Asia. Regulations governing cell-derived products in those markets have been unsettled, and changes in those regulations, or in their interpretation or enforcement, may delay or prevent sales of our products. Our supplier and our products are located in and sourced from Taiwan, and we are exposed to currency fluctuations, trade restrictions, tariffs, and political and military tensions affecting Taiwan and the surrounding region, any of which could interrupt supply or eliminate our access to a target market.”see in full comparison
“Our target markets are outside the United States and are subject to evolving regulation and geopolitical risk.”see in full comparison
“Both conditions are present. The Company has not generated any revenue and has financed its operations through advances from a related party, and the related party agreed to a twenty-four month, interest-free deferral of the $2,411,000 balance that it would not otherwise have granted. Because the total future cash payments specified by the new terms ($2,411,000) are not less than the carrying amount of the payable immediately before the restructuring ($2,411,000), no gain is recognized, the carrying amount of the payable is not adjusted, and the new effective interest rate is 0%. …”see in full comparison
“Because we currently have a stockholders’ deficit and lack independent directors, we may not satisfy the financial and governance requirements necessary to uplist to OTCQB or a national securities exchange.”see in full comparison
“The risk factors set forth below are restated in their entirety and supersede the risk factors disclosed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended January 31, 2026.”see in full comparison
“We depend on advances from a former officer and major shareholder who is under no obligation to continue funding us.”see in full comparison
Full comparison: every changed paragraph (38)
The risk factors set forth below are restated in their entirety and supersede the risk factors disclosed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended January 31, 2026.
We have not generated revenue during the threesix months ended AprilJuly 30,31, 2026. As of AprilJuly 30,31, 2026, we had cash of $8,167,$13,367, total assets of $11,432,$14,822, total liabilities of $4,517,844,$4,677,051, an accumulated deficit of $5,772,715, positive operating cash flows of $6,083$5,928,532 and a stockholders’ deficit of $4,506,412.$4,662,229. We have incurred recurring losses since inception and expect to continue incurring losses for the foreseeable future. Based on our current cash position and expected expenditure, we do not have sufficient liquidity to fund operations for the next twelve months without additional financing.
Our negative stockholders’ equity position may adversely affect investor confidence and impair our ability to obtain financing on favorable terms. Certain trading platforms and exchanges impose minimum stockholders’ equity requirements.requirements, minimum bid price requirements and independent director requirements, and we currently have no independent directors. We may need to effect a reverse stock split to satisfy minimum bid price requirements, which could adversely affect stockholder value. Our current financial condition may limit our ability to satisfy such requirements, thereby restricting our ability to uplist our common stock to OTCQB or a national securities exchange. Certain markets, including the OTCQB and the national securities exchanges, require minimum stockholders’ equity thresholds that we currently do not meet.
RISKS RELATED TO OUR DEVELOPMENT-STAGE STATUSBUSINESS AND BUSINESS STRATEGY
We are not currently conducting commercial operationsoperations, butand weour havehistorical hadrevenues aare historynot indicative of revenuefuture generation.results.
We conducted commercial operations from our fiscal year ended January 31, 2018 through our fiscal year ended January 31, 2022 and have not generated revenue since that time. We do not manufacture any products ourselves, we did not incur research and development expenses in the period ended July 31, 2026 or the fiscal year ended January 31, 2026, we have not initiated clinical trials, and we have not obtained regulatory approvals. We are re-establishing our product offerings and sales channels, but we have not entered into any sales agent agreement or clinic supply arrangement, and we will require capital to fund initial product purchases before we can resume sales. Our historical revenues were generated under different market and regulatory conditions and are not indicative of the revenue, if any, that we may generate in the future.
Although we describe a long-term strategy involving regenerative medicine technologies, including potential stem-cell and exosome-based applications, we are not currently conducting commercial manufacturing, distribution, or revenue-generating activities. We did not incur research and development expenses in the current period ended April 30, 2026, or fiscal year ended January 31, 2026, have not initiated clinical trials, and have not obtained regulatory approvals. Our limited operating history makes it difficult for investors to evaluate our prospects. As of the date of this Quarterly Report, we are not actively developing, manufacturing, or marketing any products.
Given our financial condition and development-stagethe status,early stage of our re-entry into commercial operations, we may revise or modify our business strategy. Such changes may expose us to additional risks and uncertainties and may not result in successful operations.
We currently depend on a single supplier for all of our products, and we have no written supply agreement.
We currently purchase all of our products from one supplier located in Taiwan, which owns and controls the cell culture processes, growth media and formulations used to make them. Our arrangement with the supplier is oral, we have no exclusivity arrangement with the supplier, and we have no written agreement covering future orders, pricing, quantities, delivery or quality. The supplier has advised us that future supply will not be conditioned on repayment of the $2,411,000 balance deferred on May 18, 2026 and that future orders may be placed on an advance-deposit basis or on terms of approximately 30 to 90 days, but those statements are not contractually binding and may not be honored. If the supplier ceases to supply us, changes its terms, or does not complete requalification of its production process, we would have no current source of product and no ability to resume sales until we qualified another supplier. We are evaluating additional sources of supply, but we have not qualified any alternative supplier.
Our supplier is a related party, which creates conflicts of interest.
Our supplier is wholly owned by shareholders who collectively hold more than 20% of our outstanding common shares. Our supply arrangement is oral and was not negotiated at arm’s length, and we have not adopted a formal related-party transaction policy. The terms on which we obtain products, and the supplier’s willingness to continue supplying us and to forbear on the deferred $2,411,000 balance, are subject to the interests of persons who also control a significant portion of our equity. Although we are not obligated to purchase exclusively from the supplier and are evaluating additional sources of supply, we currently have no qualified alternative.
We have not entered into any sales agent or clinic supply agreements.
Both of the sales channels we are developing depend on agreements we have not yet made. We have not appointed any sales agent for any territory or channel, and we have not entered into any supply arrangement with any medical clinic. We may not succeed in entering into these agreements on acceptable terms or at all, and even if we do, the membership and clinic channels may not generate meaningful revenue.
We will need additional capital to purchase inventory before we can resume sales.
We had cash of $13,367 as of July 31, 2026. Resuming sales requires capital sufficient to fund initial product purchases, and our supplier may require advance deposits. We have no committed source of that capital. If we cannot obtain it, we will be unable to resume sales regardless of whether we complete the agent and clinic arrangements described above.
Our target markets are outside the United States and are subject to evolving regulation and geopolitical risk.
Our initial target markets are Taiwan, Mainland China and Southeast Asia. Regulations governing cell-derived products in those markets have been unsettled, and changes in those regulations, or in their interpretation or enforcement, may delay or prevent sales of our products. Our supplier and our products are located in and sourced from Taiwan, and we are exposed to currency fluctuations, trade restrictions, tariffs, and political and military tensions affecting Taiwan and the surrounding region, any of which could interrupt supply or eliminate our access to a target market.
We depend on a small number of personnel whose compensation is accrued and unpaid.
In addition to our executive officers, we have two employees: a Vice President, Legal and Operations and a bookkeeper. Compensation for both has been accrued and remains unpaid because of our cash position, and accrued payroll represents a substantial portion of our current liabilities. If either employee were to resign, we would lose the personnel who perform our corporate, accounting, SEC reporting and tax functions, and we may be unable to replace them or to pay a replacement.
Substantially all of our liabilities are obligations to related parties. As of July 31, 2026, we owed $1,185,582 of unsecured, non-interest-bearing advances payable on demand to a former officer who is also a major shareholder, and $2,411,000 to a vendor wholly owned by shareholders who collectively hold more than 20% of our outstanding common shares, collection of which that vendor has agreed to defer, interest-free, for twenty-four months from May 18, 2026. Neither related party is obligated to extend further credit to us or to forbear beyond the agreed deferral period, and we have no committed source of financing that would permit us to repay these amounts if repayment were demanded. In addition, a former officer who is among these creditors is involved in criminal proceedings in Taiwan that are unrelated to us and to which we are not a party. The specific risks arising from these relationships are described below. See also Note 4 to our financial statements included in Item 1 of this report.
We depend on advances from a former officer and major shareholder who is under no obligation to continue funding us.
We have historically funded our operating expenses through cash advances from, and direct payment of expenses by, a former Chief Executive Officer who is also a major shareholder. That party is under no obligation to continue providing funding, and any discontinuation would materially and adversely affect our ability to remain in operation. These advances are unsecured, non-interest-bearing and payable on demand. For the amounts outstanding and the related terms, see Note 4 to our financial statements included in Item 1 of this report.
Due to Related Party
In prior years, the Company sourced all of its inventory from a vendor wholly owned by shareholders who collectively hold more than 20% of the Company’s outstanding common shares as of July 31, 2026. As of January 31, 2026, amounts due to this related party totaled $2,411,000 and are disclosed in Accounts Payable – related party on the balance sheets. As of January 31, 2026, the Company did not have written agreements governing the repayment terms of related-party balance. These obligations are unsecured, non-interest-bearing, and payable on demand.
On May 18, 2026, the Company entered into a deferred payment agreement with this related party, both parties agreed to defer collection efforts for a period of twenty-four (24) months from May 18, 2026, interest-free and the related party will not demand immediate repayment of the outstanding balance of $2,411,000. No assurance can be provided that related parties will continue to provide financial support or refrain from demanding repayment.
The Company evaluated the modification of terms of new agreement under ASC 470-60, “Troubled Debt Restructuring -TDR”, and concluded that the debt modification constitutes a Troubled Debt Restructuring (TDR). A restructuring of debt qualifies as a TDR when both of the following conditions are present:
Both conditions are present. The Company has not generated any revenue and has financed its operations through advances from a related party, and the related party agreed to a twenty-four month, interest-free deferral of the $2,411,000 balance that it would not otherwise have granted. Because the total future cash payments specified by the new terms ($2,411,000) are not less than the carrying amount of the payable immediately before the restructuring ($2,411,000), no gain is recognized, the carrying amount of the payable is not adjusted, and the new effective interest rate is 0%. Accordingly, no interest expense is recognized over the deferral period and no debt discount is recorded. As of July 31, 2026, the Company reclassified the $2,411,000 balance from current liabilities to long-term liability. No portion of the balance is due within twelve months of July 31, 2026.
As of April 30, 2026, we owed $2,411,000 to a related-party vendor, which is owned by our former officer, and $1,052,351 in advances from related parties, including advances made by a former Chief Executive Officer and Chairman of the Board. These obligations are unsecured, and are not subject to formal long-term repayment schedules, and may be payable on demand. On May 18, 2026, the Company entered into a deferred payment agreement for its accounts payable with a related party. Both parties agreed to defer collection efforts for a period of twenty-four (24) months from May 18, 2026. The continuation of related-party financial support is not assured.
We currently have a singleone director whoand also serves as our soleone executive officer.officer, Weand dothe same person does not haveserve independentin directorsboth or standing committees.roles. We have not adopted a formal related-party transaction policy. This structure may increase the risk of conflicts of interest and reduce oversight of management decisions.
ManagementAs previously reported in our Annual Report on Form 10-K for the fiscal year ended January 31, 2026, management concluded that our internal control over financial reporting was not effective as of AprilJanuary 30,31, 2026, due to insufficient segregation of duties and lack of personnel with appropriate U.S. GAAP and SEC reporting expertise. This material weakness has not been remediated as of July 31, 2026. If we fail to remediate this material weakness, we may be unable to prevent or detect material misstatements in our financial statements.
As of AprilJuly 30,31, 2026, we had federal net operating loss (“NOL”) carryforwards.carryforwards of approximately $6.2 Million . Our ability to utilize these NOLs to offset future taxable income, if any, may be significantly limited under Section 382 of the Internal Revenue Code of 1986, as amended (“Section 382”), if we experience an “ownership change” as defined in Section 382.
Because we currently have a stockholders’ deficit and lack independent directors, we may not satisfy the financial and governance requirements necessary to uplist to OTCQB or a national securities exchange.
We may seek an uplisting of our common stock. Uplisting requires compliance with financial, corporate governance, and market-based criteria, including minimum bid price, stockholders’ equity thresholds, and independent board requirements. Our current financial condition and governance structure may prevent us from meeting such criteria. We may need to effect a reverse stock split to meet minimum bid price requirements, which could adversely affect stockholder value.
Our common stock trades on the OTC Pink Limited marketplace, which generally has lower liquidity and greater volatility than national securities exchanges. Limited trading volume may result in substantial price fluctuations. The Company is not compliant with Rule 15c2-11 and intends to engage a market maker to file a Form 211 with FINRA on our behalf in September 2026. While we are not compliant, broker-dealers may not publish quotations, the stock may be limited to unsolicited trades or the Expert Market, and both liquidity and the ability to raise equity are impaired.
Given our development-stage status, lack of current revenue, minimal liquidity, significant liabilities, material weakness in internal controls, governance limitations, regulatory uncertainty, and dependence on future financing, an investment in our common stock is highly speculative and may result in the loss of your entire investment.
Companies with limited operating histories, development-stagelimited businessor models,suspended commercial operations, minimal revenues, recurring losses, or significant stock price volatility frequently become the target of securities class action litigation or stockholder derivative lawsuits. Given our development-stagesuspended status,commercial operations, going-concern uncertainty, dependence on future financing, related-party transactions, material weakness in internal control over financial reporting, and limited trading liquidity, we may be particularly susceptible to such litigation.
In addition, we may become subject to stockholder derivative actions alleging breach of fiduciary duties by our officers or director, particularly given our governance structure, related-party transactions, and development-stageour suspended commercial operations. Such actions may seek monetary damages, corporate governance changes, or other equitable relief.
Management's Discussion & Analysis (MD&A)
New heading “For the six months ended July 31, 2026, compared to the six months ended July 31, 2025”
New heading “Operating Expenses”
New heading “Provision for Income Taxes”
Largest changes
“We are currently developing two sales channels. The first is a membership subscription program directed at the longevity market in Taiwan, Mainland China and Southeast Asia, under which members would receive a specified quantity of our products according to membership level, developed both through authorized sales agents appointed for particular territories and sales channels and through direct enrollment. The second is a supply relationship with medical clinics serving the longevity market, under which we would supply products to participating clinics for provision to their existing patients. …”see in full comparison
“For the six months ended July 31, 2026, compared to the six months ended July 31, 2025”see in full comparison
“We are a biomedical company focused on the wellness, healthy aging, regenerative medicine, preventive healthcare, skincare and anti-aging markets, with an initial focus on Taiwan, Mainland China and Southeast Asia. Our business model is to identify market opportunities and end-user requirements in those markets, to direct the development and manufacture of products designed to meet them, and to sell those products through appointed sales agents and directly to end users.”see in full comparison
“However, during the six months ended July 31, 2026, and 2025, we recognized $0 and $23,172, respectively, interest and penalties on historical income tax obligations relating to fiscal year 2022, which are classified as income tax expense in accordance with ASC 740-10-45-25, we have elected to classify interest and penalties related to income tax obligations as income tax expense. Accordingly, these amounts are presented within the income tax expense line on the statement of operations and do not represent a current provision on operating income.”see in full comparison
“We currently purchase all of our finished products from one supplier located in Taiwan, which is a related party. The supplier is wholly owned by shareholders who collectively hold more than 20% of our outstanding common shares. We are not party to any exclusivity arrangement with the supplier, and we have no written supply agreement covering future orders. …”see in full comparison
Full comparison: every changed paragraph (56)
This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. These statements often can be identified by the use of terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “approximate” or “continue,” or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statementsstatement representrepresents management’s best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.
We are a biomedical company focused on the wellness, healthy aging, regenerative medicine, preventive healthcare, skincare and anti-aging markets, with an initial focus on Taiwan, Mainland China and Southeast Asia. Our business model is to identify market opportunities and end-user requirements in those markets, to direct the development and manufacture of products designed to meet them, and to sell those products through appointed sales agents and directly to end users.
We conducted commercial operations from our fiscal year ended January 31, 2018 through our fiscal year ended January 31, 2022, generating cumulative revenue of approximately $5.9 million, including $5,613,200 in the fiscal year ended January 31, 2022. Commercial sales were suspended after that period while our supplier requalified its production process and while the regulations governing cell-derived products in our target markets remained unsettled. We have maintained our supplier relationship and our personnel throughout that period and are currently re-establishing our product offerings and sales channels.
Our products are based on PCMSC, a mesenchymal stem cell derived from placental tissue, and on exosome-based materials derived from those cells, with applications in wellness, healthy aging, regenerative medicine, preventive healthcare, skincare and anti-aging. Our products are manufactured by our supplier in Taiwan, which owns and controls the applicable cell culture processes, growth media and formulations. We do not own any issued patents and have no patent applications pending, and we conducted no research and development activities during the fiscal years ended January 31, 2026 and 2025.
We are currently developing two sales channels. The first is a membership subscription program directed at the longevity market in Taiwan, Mainland China and Southeast Asia, under which members would receive a specified quantity of our products according to membership level, developed both through authorized sales agents appointed for particular territories and sales channels and through direct enrollment. The second is a supply relationship with medical clinics serving the longevity market, under which we would supply products to participating clinics for provision to their existing patients. As of the date of this report we have not entered into any agent agreements or clinic supply arrangements. Longer-term objectives include development of a stem cell bank, generation of data and processes capable of being licensed, and expansion of applications in regenerative medicine and related fields.
We currently purchase all of our finished products from one supplier located in Taiwan, which is a related party. The supplier is wholly owned by shareholders who collectively hold more than 20% of our outstanding common shares. We are not party to any exclusivity arrangement with the supplier, and we have no written supply agreement covering future orders. On May 18, 2026, we and the supplier entered into an agreement deferring payment of $2,411,000 of outstanding payables owed to the supplier for twenty-four months without interest (see Note 4 to our financial statements included in Item 1 of this report). The supplier has advised us that future product supply will not be conditioned on repayment of that balance and that future orders may be placed on an advance-deposit basis or on payment terms of approximately 30 to 90 days; those statements are not contractually binding. We expect to enter into specific agreements covering individual orders as those orders are placed, and we are also evaluating additional sources of supply.
In addition to our executive officers, we have two employees: a Vice President, Legal and Operations, who is responsible for our corporate, accounting, SEC reporting, tax and public-market matters and for business development, and a bookkeeper responsible for our accounting records. Compensation for both has been accrued and remains unpaid as a result of our cash position. We do not own or lease any material real property; our principal executive offices are virtual and are provided by a third party under a month-to-month arrangement, and we do not maintain our own laboratory or manufacturing facility.
During the six months ended July 31, 2026, and 2025, we did not generate any revenue. We have not generated revenue since the fiscal year ended January 31, 2022, and our ability to resume sales depends on obtaining capital sufficient to fund initial product purchases and on completing the agent and clinic arrangements described above.
We are a development-stage biomedical company focused on cell-based technologies for regenerative and preventative health applications. Our business model historically involved sourcing stem cells and exosome products from a related-party vendor and reselling those products to customers. We are currently evaluating future commercialization opportunities involving regenerative medicine, cell-based technologies, and related healthcare applications.
During the three months ended April 30, 2026, and 2025, we did not generate any revenue as we restructured our commercial strategy, evaluated supplier and regulatory considerations, and assessed future business direction.
As of AprilJuly 30,31, 2026, we have not reinitiated revenue-generating operations.
The following summary of our results of operations should be read in conjunction with our unaudited financial statements for the period ended AprilJuly 30,31, 2026, which are included herein.
Our operating results for the three and six months ended AprilJuly 30,31, 2026, and 2025 and the changes between those periods for the respective items are summarized as follows.
For the three months ended AprilJuly 30,31, 2026, compared to the three months ended AprilJuly 30,31, 2025
We generated no revenue during the three months ended AprilJuly 30,31, 2026, and 2025, respectively.2025. We are currently focusing on restructuring our product strategy and developing long-term partnerships rather than pursuing short-term sales.
Operating expenses were $75,844$161,817 for the three months ended AprilJuly 30,31, 2026, compared with $69,147$99,067 for the three months ended AprilJuly 30,31, 2025. For the three months ended AprilJuly 30,31, 2026, and 2025, the operating expenses were primarily attributed to professional fees of $12,200$98,174 and $3,500,$35,200 salariesrelating andto relatedour status as a public company, payroll expenses of $57,813 and $57,813, depreciation of $2,489$1,660 and $2,489$2,490 and general and administrative expenses of $3,342$4,170 and $5,345,$3,564, respectively.
Other Income
During the three months ended July 31, 2026, the Company received security rent deposit refund of $6,000. The security deposit was expensed in prior year, the refund of $6,000 was recognized as other income.
Provision for Income Taxes Expenses
We did not record a current income tax provision on our operating losses for the three months ended AprilJuly 30,31, 2026, and 2025, due to our net operating loss position and a full valuation allowance against deferred tax assets.
However, during the three months ended AprilJuly 30,31, 2026, and 2025, we recognized $0 and $11,394,$11,778, respectively, interest and penalties on historical income tax obligations relating to fiscal year 2022, which are classified as income tax expense in accordance with ASC 740-10-45-25, we have elected to classify interest and penalties related to income tax obligations as income tax expense. Accordingly, these amounts are presented within the income tax expense line on the statement of operations and do not represent a current provision on operating income.
We had a net loss of $75,844$155,817 for the three months ended AprilJuly 30,31, 2026, and $80,541$110,845 for the three months ended AprilJuly 30,31, 2025. The decreaseincrease in net loss of $4,697$44,972 was primarily due to an increase in operating expenses, includingother professionalincome, fees,and a decrease in general and administrative expenses and provision for income tax expenses.
For the six months ended July 31, 2026, compared to the six months ended July 31, 2025
Revenue
We generated no revenue during the six months ended July 31, 2026, and 2025. We are currently focusing on restructuring our product strategy and developing long-term partnerships rather than pursuing short-term sales.
Operating Expenses
Operating expenses were $237,661 for the six months ended July 31, 2026, compared with $168,214 for the six months ended July 31, 2025. For the six months ended July 31, 2026, and 2025, the operating expenses were primarily attributed to professional fees of $110,374 and $38,700 relating to our status as a public company, payroll expenses of $115,625 and $115,625, depreciation of $4,149 and $4,979 and general and administrative expenses of $7,513 and $8,910, respectively.
Other Income
During the six months ended July 31, 2026, the Company received security rent deposit refund of $6,000. The security deposit was expensed in prior year, the refund of $6,000 was recognized as other income.
Provision for Income Taxes
We did not record a current income tax provision on our operating losses for the six months ended July 31, 2026, and 2025, due to our net operating loss position and a full valuation allowance against deferred tax assets.
However, during the six months ended July 31, 2026, and 2025, we recognized $0 and $23,172, respectively, interest and penalties on historical income tax obligations relating to fiscal year 2022, which are classified as income tax expense in accordance with ASC 740-10-45-25, we have elected to classify interest and penalties related to income tax obligations as income tax expense. Accordingly, these amounts are presented within the income tax expense line on the statement of operations and do not represent a current provision on operating income.
Net Loss
We had a net loss of $231,661 for the six months ended July 31, 2026, and $191,386 for the six months ended July 31, 2025. The increase in net loss of $40,275 was primarily due to an increase in operating expenses, other income, and a decrease in provision for income tax expenses.
As of July 31, 2026, we had total assets of $14,822, total liabilities of $4,677,051 and a stockholders’ deficit of $4,662,229. The principal balance sheet movements during the six months ended July 31, 2026, were the reclassification of $2,411,000 of accounts payable - related party from current liabilities to long-term liability in connection with the deferred payment agreement entered into on May 18, 2026, and an increase in advances - related party to $1,185,582 as of July 31, 2026 from $1,037,983 as of January 31, 2026, reflecting operating expenses paid directly by a related party on our behalf. Our property and equipment are substantially fully depreciated.
The following table summarizes our changes in working capital deficiency as of AprilJuly 30,31, 2026, and January 31, 2026.
As of AprilJuly 30,31, 2026, and January 31, 2026, current assets were comprised of $8,167$13,367 and $2,084 in cash, $1,605$1,455 and $8,443 in prepaid expenses, respectively.
As of AprilJuly 30,31, 2026, and January 31, 2026, current liabilities were comprised of $2,411,000$0 and $2,411,000 in accounts payable - related party, $711,641$139,420 and $652,027$169,455 in accounts payable and other payables, $598,197 and $482,572 in payroll liability, $342,852 and $344,234 in income tax and franchise tax payable and $1,052,351$1,185,582 and $1,037,983in advances from related party, respectively.
Our working capital deficiency increasedreduced by $73,355,$2,183,488, or 1.65%,49.23%, to $4,508,072$2,251,229 as of AprilJuly 30,31, 2026, compared to working capital deficiency of $4,434,717 as of January 31, 2026. The increaseimprovement in working capital was primarily due to the reclassification of $2,411,000 of accounts payable - related party to a long-term loan payable pursuant to the deferred payment agreement dated May 18, 2026; total liabilities increased from $4,445,244 to $4,677,051 over the same period (see Financial Statements, Note 4), partly offset by an increase in advances from related party and accounts payable and other payables. Advances paid directly by related parties on behalf of the Company for operating expenses are reflected as operating activities, while cash proceeds received directly from related parties are classified as financing activities. A substantial portion of the Company’s liabilities consists of obligations to related parties that are unsecured, non-interest-bearing, and payable on demand, with no formal repayment terms. Our related party accounts payable is subject to the May 18, 2026, deferral agreement. Given the Company’s current financial condition, there can be no assurance that the Company will be able to continue operations absent additional capital. The Company may be required to significantly curtail or cease operations if financing is not obtained in the near term.
Given the Company’s current financial condition, there can be no assurance that the Company will be able to continue operations absent additional capital. The Company may be required to significantly curtail or cease operations if financing is not obtained in the near term.
The income tax payable balance primarily relates to historical income tax liabilities and franchise tax expenses, and no current income tax was recognized due to our net operating loss position and full valuation allowance. During the threesix months ended AprilJuly 30,31, 2026, and 2025, the Company recognized $0 and $11,394,$23,172, respectively, in interest and penalties associated with historical income tax liabilities and franchise tax expensesobligations relating to fiscal year 2022,2022. In accordance with ASC 740-10-45-25, these interest and penalties associated with income tax obligations are classified as income tax expense in accordancethe withCompany’s ASCstatements 740-10-45-25.of operations.
During the six months ended July 31, 2026, and 2025, the Company paid income taxes of $0 and $0, respectively, During the six months ended July 31, 2026, the Company also paid $1,382 in franchise taxes, which reduced the related historical tax payable balance.
The following table summarizes our cash flows for the threesix months ended AprilJuly 30,31, 2026, and 2025:
We have funded our activities primarily through shareholderadvances advances,from whichrelated-party shareholders. Those advances were historically discretionary and not subject to a written agreement. On May 18, 2026, we entered into a deferred payment agreement with a related party covering $2,411,000 of those obligations, as described above and in Note 4 to our financial statements. Advances outside that agreement remain discretionary, unsecured and payable on demand. We continue to rely on external funding and available cash balances to meet our working-capital needs. Management believes that additional capital will be required to support operations over the next twelve months.
We expect to continue to require additional capital to support operations, research, and regulatorythe initiatives.resumption of product sales. Management is exploring potential sources of financing, including private placements of equity or debt securities and strategic partnerships. There is no assurance that additional funding will be available on acceptable terms. If we cannot secure sufficient financing, we may need to delay or scale back parts of our business plan.
Net cash provided by operating activities was $11,283 for the six months ended July 31, 2026. This inflow does not represent cash generated by our operations; it arises because a related party paid operating expenses directly on our behalf. Net cash provided by operating activities consisted of a net loss of $231,661, offset by depreciation expense of $4,149, operating expenses of $147,599 paid directly by a related party on our behalf, and a net change in working capital of $92,578, less franchise taxes paid of $1,382.
We have generated positive cash flows from operating activities. For the three months ended April 30, 2026, net cash flows provided by operating activities was $6,083, consisting of a net loss of $75,844, reduced by depreciation expense of $2,489, advances from related party for operating expenses of $14,368, a net change in working capital of $66,452 and increased by franchise tax expenses payment of $1,382.
For the threesix months ended AprilJuly 30,31, 2025, net cash flows used in operating activities $787,was $1,973, consisting of a net loss of $80,541,$191,386, reduced by depreciation expense of $2,489,$4,979, advances from related party for operating expenses of $30,434,$104,415, income tax expenses payable of $11,394$22,372 and a net change in working capital of $35,437.$57,647.
We had no investing activitiesactivity during the threesix months ended AprilJuly 30,31, 2026, and 2025.
During the threesix months ended AprilJuly 30,31, 2026, and 2025, thenet Companycash receivedprovided by financing activities consisted of related party advances of $0 and $515 by financing activities,$2,500, respectively.
During the three months ended April 30, 2026, and 2025, we had financing inflow of $0 and $500 from advances from related party, $0 and $15 from bank overdraft activity, respectively.
Our financial statements have been prepared assuming we will continue as a going concern. As disclosed in Note 2 to our financial statements, as of AprilJuly 30,31, 2026, we had a net loss of $75,844$231,661 and an accumulated deficit of $5,772,715,$5,928,532, and a working capital deficiency of $4,508,072,$2,251,229. Net cash provided by operating activities of $11,283 for the period arose solely from operating expenses paid directly by a related party on our behalf and positivedoes operatingnot represent cash flowsgenerated of $6,083, which is due toby our limited operations. These factors raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these financial statements. Our ability to continue as a going concern depends upon our ability to obtain additional funding, restructuring related-party obligations, and implement a business plan that generates sustainable revenues. There can be no assurance that we will be successful in these efforts. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be unable to continue as a going concern. Management’s plans to alleviate substantial doubt are dependent upon obtaining additional financing and therefore cannot be considered probable of being effectively implemented.
As of AprilJuly 30,31, 2026, we did not have any off-balance sheet arrangements.
While existing working capital and anticipated financing sources may provide limited support for our operations, our current cash resources are not sufficient to fund our operations over the next twelve months without additional financing. We will require additional capital to continue operations and execute our business plan. There can be no assurance that such financing will be available on acceptable terms, or at all. If we are unable to obtain adequate funding, we may be required to delay, scale back, or discontinue certain or all of our operations. In addition to funding our operating expenses, we will require capital to fund initial purchases of product inventory before we can resume sales. We have no committed source of that capital, and the amount and timing of any resumption of sales will depend on the capital we are able to raise and on completing the sales agent and clinic arrangements described under “Overview” above.
Our financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of financial statements requires management to make estimates and assumptions, including, but are not limited to tax expense valuation allowances, and the assessment of the Company’s ability to continue as a going concern. Our significant accounting policies are described in Note 3 to the financial statements. We consider the following policies and estimates to be critical because they involve significant judgments and assumptions and could materially affect our financial condition and results of operations. Critical estimates are those estimates that in accordance with U.S. GAAP, involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial statements. Management has determined that our most critical accounting estimates are those relating to stock-based compensation, lease accounting, andthe going concern assessment.assessment and to income taxes, including the valuation allowance recorded against our deferred tax assets.
Significant estimates and assumptions reflected in the financial statements for the quarter ended AprilJuly 30,31, 2026, include, but are not limited to:
VSBC insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
No Form 4 stock transactions in this period.
Well-known investors holding VSBC (13F)
None of the 59 investors we track reported a position in their latest 13F.